Selected article for: "high flow nasal and mechanical ventilation"
Author: Huayan Xu; Keke Hou; Hong Xu; Zhenlin Li; Huizhu Chen; Na Zhang; Rong Xu; Hang Fu; Ran Sun; Lingyi Wen; Linjun Xie; Hui Liu; Kun Zhang; Joseph B Selvanayagam; Chuan Fu; Shihua Zhao; Zhigang Yang; Ming Yang; Yingkun Guo
Title: Acute Myocardial Injury of Patients with Coronavirus Disease 2019
  • Document date: 2020_3_8
    • ID: jg6v644y_31
    Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.05.20031591 doi: medRxiv preprint Table 3 shows the main management strategies, comorbid conditions, and clinical outcomes of all the COVID-19 patients. In the AMI group, in addition to antiviral and antibiotic therapies, cardioprotective medications such as amiodarone and cedilla were used by four patients to improve the cardiac function.....
    Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.05.20031591 doi: medRxiv preprint Table 3 shows the main management strategies, comorbid conditions, and clinical outcomes of all the COVID-19 patients. In the AMI group, in addition to antiviral and antibiotic therapies, cardioprotective medications such as amiodarone and cedilla were used by four patients to improve the cardiac function. However, the non-definite AMI patients with and without cardiac markers abnormalities did not use cardioprotective medication. All the 53 patients were administered nasal cannula oxygen therapy during admission for respiratory support; non-invasive ventilation or high-flow nasal cannula oxygen therapy was performed for five AMI and three non-definite AMI patients with cardiac marker abnormalities. Notably, in the AMI group, invasive mechanical ventilation was used in three patients and ECMO in one patient due to extremely severe ARDS.

    Search related documents:
    Co phrase search for related documents
    • AMI group and cardiac marker: 1, 2, 3, 4, 5
    • AMI group and cardiac marker abnormality: 1
    • AMI group and clinical outcome: 1, 2, 3, 4
    • antibiotic antiviral therapy and cardiac function: 1
    • antibiotic antiviral therapy and cardiac marker: 1
    • antibiotic antiviral therapy and clinical outcome: 1
    • antibiotic antiviral therapy and high flow: 1
    • antibiotic antiviral therapy and invasive mechanical ventilation: 1, 2, 3
    • cannula oxygen therapy and cardiac function: 1
    • cannula oxygen therapy and cardiac function improve: 1
    • cannula oxygen therapy and clinical outcome: 1, 2
    • cannula oxygen therapy and high flow: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cannula oxygen therapy and high flow nasal: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cannula oxygen therapy and high flow nasal non invasive ventilation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • cannula oxygen therapy and invasive mechanical ventilation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • cardiac function and ECMO patient: 1, 2
    • cardiac function and high flow: 1, 2, 3
    • cardiac function and high flow nasal: 1, 2
    • cardiac function and invasive mechanical ventilation: 1, 2, 3, 4, 5, 6